GSK plc

GSK plc Enterprise Value

The Enterprise Value (EV) of GSK plc (GSK.L) as of Nov 6, 2026 is 101.91 B GBP. In the previous year, Enterprise Value (EV) was 100.63 B GBP — a change of 1.28% (higher).

Enterprise Value

101.91 BGBP

YoY

1.28%

Last updated:

Enterprise Value (EV) of GSK plc is 2025 101.91 B GBP. Enterprise Value (EV) of GSK plc was 2024 100.63 B GBP. It decreases by 1.28% higher compared to the previous year.

The GSK plc Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
109.46 B GBP
Jan 1, 2019
113.28 B GBP
Jan 1, 2020
108.33 B GBP
Jan 1, 2021
107.39 B GBP
Jan 1, 2022
100.66 B GBP
Jan 1, 2023
100.38 B GBP
Jan 1, 2024
100.63 B GBP
Jan 1, 2025
101.91 B GBP
The GSK plc Enterprise Value history
YEAREnterprise ValueYoY
101.91 BGBP+1.28%
100.63 BGBP+0.25%
100.38 BGBP-0.28%
100.66 BGBP-6.26%
107.39 BGBP-0.87%
108.33 BGBP-4.36%
113.28 BGBP+3.49%
109.46 BGBP+8.88%
100.53 BGBP-0.62%
101.16 BGBP+3.14%
98.08 BGBP-3.59%
101.73 BGBP—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GSK plc Stock analysis

What does GSK plc do? GSK plc generates revenue through its Pharmaceuticals and Vaccines segments, which focus on developing and selling prescription medicines and vaccines. The Pharmaceuticals segment offers products in Respiratory, HIV, Specialty, and Classic and Established categories, targeting acute and chronic diseases. The Vaccines segment provides over 40 vaccines for pediatric, adolescent, adult, and older populations, including travel vaccines. Customers include healthcare providers, hospitals, and consumers purchasing over-the-counter products. GSK's brand portfolio spans prescription medicines like those for Respiratory and HIV, alongside vaccines such as those for pediatric and adult health. The company's research focuses on six therapeutic areas: Respiratory diseases, HIV/infectious diseases, Vaccines, Immuno-inflammation, Oncology, and Rare diseases. This research drives product development for both segments, ensuring a steady pipeline of medicines and vaccines. The company's products are distributed globally, with the Pharmaceuticals business targeting healthcare professionals and the Vaccines business serving public health programs and individual consumers. GSK's strategy emphasizes innovation in key therapeutic areas to address unmet medical needs, leveraging its extensive research and development capabilities to maintain market leadership. GSK plc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GSK plc stock

Enterprise Value (EV) of GSK plc is 101.91 B GBP in 2025.

Enterprise Value (EV) of GSK plc changed from 100.63 B GBP to 101.91 B GBP, representing a 1.28% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) GSK plc since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s GBP, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' GBP varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s GSK plc with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — GSK plc

All Key Metrics — GSK plc